¹ú¼ÊÓÐÊý²¡ÈÕØ¹Ø×¢Ó¤¶ù¾·ÂÎÖ¢£¬£¬£¬£¬£¬£¬£¬£¬ÈÃÓÐÊý±»Íû¼û
¹ú¼ÊÓÐÊý²¡ÈÕ
¡°´ÉÍÞÍÞ¡±¡¢¡°½¥¶³ÈË¡±¡¢¡°ÔÂÁÁº¢×Ó¡±¡¢¡°µç±¦±¦¡±¡¡ÕâЩ¿É°®µÄÃû×Ö±³ºó£¬£¬£¬£¬£¬£¬£¬£¬×Åʵ¶ÔÓ¦µÄÊÇÒ»¸ö¸öÓÐÊý²¡¡£¡£¡£¡£¡£¡£¡£¡£¡°µç±¦±¦¡±¼´ÊǶԡ°Ó¤¶ù¾·ÂÎÖ¢¡±»¼¶ùµÄ³Æºô£¬£¬£¬£¬£¬£¬£¬£¬ÓÉÓÚº¢×Ó·¢²¡Ê±¡°ò¥Êס±¡¢¡°Óµ±§¡±µÄÖ¢×´Ïñ´¥µçÒ»Ñù¶øµÃÃû¡£¡£¡£¡£¡£¡£¡£¡£
½ñÌìÊÇ2ÔÂ28ÈÕ£¬£¬£¬£¬£¬£¬£¬£¬Ò²Êǹú¼ÊÓÐÊý²¡ÈÕ¡£¡£¡£¡£¡£¡£¡£¡£½ñÄê¹ú¼ÊÓÐÊý²¡ÈÕµÄÖ÷ÌâÊÇ¡°Share Your Colours¡±£¨·ÖÏíÄãµÄÉúÃüÉ«²Ê£©¡£¡£¡£¡£¡£¡£¡£¡£
ÓÐÊý²¡²¢²»ÓÐÊý£¬£¬£¬£¬£¬£¬£¬£¬ÔçÕïÔçÖÎÊÇÒªº¦
?¡°Ò©¡±ÓÐËùÒÀ£¬£¬£¬£¬£¬£¬£¬£¬ÕÕÁÁ¡°Éú¶øÓÐÊý¡±µÄËûÃÇ
³ýÁËÄÑÒÔÈ·Õ£¬£¬£¬£¬£¬£¬£¬ÖÎÁÆÒ©ÎïµÄȱ·¦ÊÇÓÐÊý²¡»¼ÕßÖÎÁÆÂ·ÉÏÒ»´óÄÑÌâ¡£¡£¡£¡£¡£¡£¡£¡£È«Çò7000¶àÖÖÓÐÊý²¡£¬£¬£¬£¬£¬£¬£¬£¬ÓÐÒ©¿ÉÖεıÈÀýȱ·¦10%¡£¡£¡£¡£¡£¡£¡£¡£ºÜÐÒÔË£¬£¬£¬£¬£¬£¬£¬£¬ISÊÇÆäÖÐÖ®Ò»¡£¡£¡£¡£¡£¡£¡£¡£
°±¼ºÏ©Ëá×÷ΪISÒ»ÏßÖÎÁÆÒ©Î£¬£¬£¬£¬£¬£¬£¬TSC°éISÊ×ѡҩÎ£¬£¬£¬£¬£¬£¬£¬ÒѾÔÚÅ·ÖÞ¹ú¼ÒÉÏÊÐ30ÓàÄê4¡£¡£¡£¡£¡£¡£¡£¡£Î¬¸ñ¶¨?(°±¼ºÏ©Ëá¿Ú·þÈÜÒºÓÃÉ¢)ÓÚ2022ÄêÔÚÖйúÕýʽÉÏÊУ¬£¬£¬£¬£¬£¬£¬£¬ÊǺ£ÄÚÊ׸öÕýʽÉÏÊеݱ¼ºÏ©Ëá¡£¡£¡£¡£¡£¡£¡£¡£ÆäδÔÚº£ÄÚÉÏÊÐ֮ǰ£¬£¬£¬£¬£¬£¬£¬£¬º£ÄÚ¹ØÓÚÕâÒ»¼²²¡µÄÖÎÁÆ´¦ÔÚÉÙÒ©»òÎÞÒ©¿ÉÓõĽ׶Σ¬£¬£¬£¬£¬£¬£¬£¬»¼¶ùÓÃÒ©ÐèҪרÃÅ´ÓÍâÑó´ú¹º£¬£¬£¬£¬£¬£¬£¬£¬²¢ÇÒÓÐЩҩÎïÓÉÓÚÇå¾²ÎÊÌ⣬£¬£¬£¬£¬£¬£¬£¬±£´æÓÃÒ©Òþ»¼£¬£¬£¬£¬£¬£¬£¬£¬ÔçǰÓÉÓÚÒßÇéÔµ¹ÊÔÓÉ£¬£¬£¬£¬£¬£¬£¬£¬¸üÊÇʱ³£ÃæÁÙ¶ÏÒ©µÄΣº¦¡£¡£¡£¡£¡£¡£¡£¡£
°±¼ºÏ©ËáµÄ×÷ÓûúÖÆÖ÷ÒªÊÇͨ¹ý²»¿ÉÄæµØÒÖÖÆGABAת°±Ã¸À´ÒÖÖÆGABAµÄÆÊÎö´úл£¬£¬£¬£¬£¬£¬£¬£¬´Ó¶øÌá¸ß¾þÄÔÖÐGABAµÄŨ¶È¡£¡£¡£¡£¡£¡£¡£¡£¸ÃÒ©¿ÉÒÔʵʱ¡¢ÓÐÓÿØÖÆ»¼¶ùñ²ðï¾·ÂΣ¬£¬£¬£¬£¬£¬£¬£¬ÏÔןÄÉÆÔ¤ºó£¬£¬£¬£¬£¬£¬£¬£¬Ìá¸ßIS»¼¶ùÉúÑÄÂʼ°ÉúÑÄÖÊÁ¿5-6¡£¡£¡£¡£¡£¡£¡£¡£
2021Äê12Ô£¬£¬£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÓëÖйú¿¹ñ²ðïÐ»á¸æ¿¢Õ½ÂÔÏàÖú£¬£¬£¬£¬£¬£¬£¬£¬ÅäºÏ½¨Éè½á½ÚÐÔÓ²»¯¼°ñ²ðïÓÐÊý²¡×¨²¡Î¯Ô±»á£¬£¬£¬£¬£¬£¬£¬£¬Íƶ¯º£ÄÚñ²ðïÓÐÊý²¡ÕïÁÆË®Æ½µÄÌáÉý£¬£¬£¬£¬£¬£¬£¬£¬Èøü¶àµÄ»¼¶ùÄܽÓÊÜÔçÕï¡¢ÔçÖΡ£¡£¡£¡£¡£¡£¡£¡£ÎªÇÐʵÓÐÓõØ×ÊÖú»¼¶ù¼ÒÍ¥¼õÇáÓÃÒ©¾¼Ã¼ç¸º£¬£¬£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Æô¶¯»¼Õ߹ذ®¸£ÀûÍýÏ룬£¬£¬£¬£¬£¬£¬£¬Ð¯ÊÖÐÐҵר¼Ò´Ó¼²²¡ÕïÖΡ¢»¼ÕßÔ®Öú¡¢ÓÃÒ©°ü¹Ü¡¢¼ÒÍ¥¹Ø°®µÈ·½Ãæ½â¾ö²¿·ÖÓÐÊý²¡»¼Õß¼°Æä¼ÒÍ¥ÄÑÌâ¡£¡£¡£¡£¡£¡£¡£¡£2022Ä꣬£¬£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³ÉÔ±ÆóÒµÍò°îÒ½Ò©¾ÙÐÐÎåÊ®Óೡ»¼Õß¿ÆÆÕ¹«Òæ½²×ù£¬£¬£¬£¬£¬£¬£¬£¬»¼Õ߹ذ®¸£ÀûÍýÏë¹²»Ý¼°1300Ãû»¼¶ù£¬£¬£¬£¬£¬£¬£¬£¬¼«´óµÄ¼õÇáÁË»¼Õß¾¼Ã¼ç¸º£¬£¬£¬£¬£¬£¬£¬£¬ÌáÉýÒ©Îï¿É¼°ÐÔÓëÒÀ´ÓÐÔ¡£¡£¡£¡£¡£¡£¡£¡£
³ýÁËIS£¬£¬£¬£¬£¬£¬£¬£¬ÉÐÓÐÒ»ÖÖÓÐÊýµÄ¼²²¡¶à·¢ÓÚ¶ùͯ¡ª¡ªÂýÐÔÈâÑ¿Ö×(chronic granulomatous disease,CGD)£¬£¬£¬£¬£¬£¬£¬£¬ÊÇÖÂËÀÐÔÒÅ´«ÐÔ°×ϸ°û¹¦Ð§È±ÏÝ£¬£¬£¬£¬£¬£¬£¬£¬¶àΪÐÔÁªÒþÐÔÒÅ´«¡£¡£¡£¡£¡£¡£¡£¡£Ñ¬È¾ÊÇCGD»¼¶ù×î³£¼ûµÄÁÙ´²ÌåÏÖ£¬£¬£¬£¬£¬£¬£¬£¬Ö÷Òª²¢·¢Ö¢¼ûÓÚÖÖÖÖÔàÆ÷»¯Å§ÐÔѬȾ£¬£¬£¬£¬£¬£¬£¬£¬È縹ǻŧÖס¢¸ÎŧÖס¢ÄÔĤÑס¢ÑÏÖØÕß±¬·¢°ÜѪ֢¶øÎ£¼°ÉúÃü¡£¡£¡£¡£¡£¡£¡£¡£¶øÙ¤Âí×ÌÈÅËØ£¨IFN¦Ã£©µÄÓ¦ÓÃÄÜÓÐÓÿØÖÆCGD»¼ÕßµÄѬȾ²¢¸ÄÉÆÉúÑÄÇéÐΣ¬£¬£¬£¬£¬£¬£¬£¬Îª»¼¶ùµÄ¼²²¡ÖÎÀí´øÀ´Ã÷È·µÄ»ñÒæ7¡¢8¡£¡£¡£¡£¡£¡£¡£¡£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³ÉÔ±ÆóÒµ×ÔÖ÷Ñз¢ÇÒÉú²úµÄIFN¦Ã£¬£¬£¬£¬£¬£¬£¬£¬Îªº£ÄÚΨһIFN¦Ã£¬£¬£¬£¬£¬£¬£¬£¬×ÝȻÿһ´ÎÆô¶¯Ò©ÎïÉú²úµÄ±¾Ç®´óÓÚÊÕÈ룬£¬£¬£¬£¬£¬£¬£¬³Ð¼Ì¡°¹Ø°®ÉúÃü¡±µÄ¼ÛÖµ¹Û£¬£¬£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÈÔÒ»Á¬Éú²ú£¬£¬£¬£¬£¬£¬£¬£¬ÖÂÁ¦Îª»¼¶ù¼ÒÍ¥´øÀ´ºã¾ÃÎÞ²¡ÉúÑĵÄÏ£Íû¡£¡£¡£¡£¡£¡£¡£¡£
²»Òò¼²²¡ÓÐÊý¶øÖÃÈôØèÎÅ£¬£¬£¬£¬£¬£¬£¬£¬²»ÒòȱҽÉÙÒ©¶øÖÃÖ®²»²Ç£¬£¬£¬£¬£¬£¬£¬£¬ÓÐÊý²¡ÈºÌåÐèÒªÉç»á¸÷·½¹Ø×¢¡£¡£¡£¡£¡£¡£¡£¡£ÌìÆø½¥Å¯£¬£¬£¬£¬£¬£¬£¬£¬Ñô¹âÕýºÃ£¬£¬£¬£¬£¬£¬£¬£¬ÈÃÎÒÃÇÒ»ÆðÆð¾¢£¬£¬£¬£¬£¬£¬£¬£¬½«Ï£ÍûµÄ¹âÕÕ½øÃ¿Ò»¸öÓÐÊý²¡»¼ÕߵļÒÍ¥£¬£¬£¬£¬£¬£¬£¬£¬ÈÃÏ£Íû²»ÔÙÓÐÊý¡£¡£¡£¡£¡£¡£¡£¡£
ÑÓÉìÔĶÁ£ºÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÓëÓÐÊý²¡
2019Äê9Ô£¬£¬£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¼ÓÈëÖйúÓÐÊý²¡Í¬ÃË¡£¡£¡£¡£¡£¡£¡£¡£¸ÃͬÃËÓɱ±¾©ÐºÍÒ½Ôº¡¢ÖйúÒ½Ò©Á¢ÒìÔö½ø»á¡¢ÖйúҽԺлáµÈǣͷÌᳫ£¬£¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚÍÆ¶¯Ò½Ñ§ÔÚÓÐÊý²¡Ñо¿·½ÃæÈ¡µÃÖØ´óÍ»ÆÆ£¬£¬£¬£¬£¬£¬£¬£¬ÌáÉýÓÐÊý²¡·ÀÖÎÓë°ü¹Üˮƽ£¬£¬£¬£¬£¬£¬£¬£¬Ôö½øÓÐÊý²¡ÁÙ´²¡¢¿ÆÑÐÓë¹Â¶ùÒ©¿ª·¢µÄÐͬÁ¢Òì¡£¡£¡£¡£¡£¡£¡£¡£
2020Äê12ÔÂ23ÈÕ£¬£¬£¬£¬£¬£¬£¬£¬ÔÚÉϺ£ÊÐÓÅÉúÓÅÓý¿ÆÑ§Ð»á£¨ÉϺ£Êи¾Ó×±£½¡Ð»á£©¡¢ÉϺ£ÊÐÓÐÊý²¡·ÀÖλù½ð»á¡¢ÉϺ£¸ßˮƽµØ·½¸ßÐ£ÖØµãÁ¢ÒìÍŶӣ¨¶ùͯ¿µ½¡Î¬»¤ÓëÔö½ø£©ÏîĿר¼Ò×éµÄÖ¸µ¼Ï£¬£¬£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©Ð¯ÊÖÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾¹«Òæ»ù½ð»á¡¢¸´µ©´óѧÁ¥Êô¶ù¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÅäºÏÆô¶¯¡°ÐÇÑ¿¡±¶ùͯÓÐÊý²¡¹Ø°®×¨Ïî»ù½ð£¬£¬£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚΪ¸ü¶à¶ùͯÓÐÊý²¡»¼ÕßÌṩȫÉúÃüÖÜÆÚµÄÕչ˺͹ذ®¡£¡£¡£¡£¡£¡£¡£¡£
2022Äê1Ô£¬£¬£¬£¬£¬£¬£¬£¬ÓÉÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³ÉÔ±ÆóÒµÍò°îÒ½Ò©Òý½øµÄÖйúÊ׸öÈë¿Ú°±¼ºÏ©ËáÉ¢¼Á¡ª¡ªÎ¬¸ñ¶¨?ÉÏÊУ¬£¬£¬£¬£¬£¬£¬£¬Ö÷ÒªÓÃÓÚ1¸öÔµ½2ËêÓ¤¶ùµÄÓ¤¶ù¾·ÂÎÖ¢£¬£¬£¬£¬£¬£¬£¬£¬¸ÃÒ©¿ÉÒÔʵʱ¡¢ÓÐÓÿØÖÆ»¼¶ùñ²ðï¾·ÂΣ¬£¬£¬£¬£¬£¬£¬£¬ÏÔןÄÉÆÔ¤ºó£¬£¬£¬£¬£¬£¬£¬£¬Ìá¸ßIS»¼¶ùÉúÑÄÂʼ°ÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£¡£¡£¡£
ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¼¯ÍÅÆð¾¢ÏìÓ¦¹ú¼Ò¶¦Á¦´ó¾ÙÌᳫÁÙ´²¼±ÐèºÍÓÐÊý²¡Ò©ÎïµÄ×¢²áÑз¢£¬£¬£¬£¬£¬£¬£¬£¬ÏÖÔÚͨ¹ýÔÊÐíÒý½øµÄģʽ£¬£¬£¬£¬£¬£¬£¬£¬ÔÚÓ¤¶ù¾·ÂÎÖ¢¡¢ÌØ·¢ÐÔ·ÎÏËά»¯¡¢·Î¶¯Âö¸ßѹµÈ˳Ӧ֢£¨²Î¿¼¹ú¼ÒÎÀÉú¿µ½¡Î¯Ô±»áÐû²¼µÄ¡¶µÚÒ»ÅúÓÐÊý²¡Ä¿Â¼¡·£©ÓµÓÐÓÐÊý²¡Ò©Î£¬£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚÌá¸ßÁ¢ÒìÖÎÁÆÒ©ÎïÔÚÓÐÊý²¡»¼ÕßÖеĿɼ°ÐÔ¡£¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1¡¢¹ù»¢, Ö£àþ. Ó¤¶ù¾·Âι²Ê¶½â¶Á[J]. ÊÊÓöù¿ÆÁÙ´²ÔÓÖ¾, 2011, 26(12):978-980.
2¡¢Curatolo P, et al. Eur J Paediatr Neurol.?2018 Sep;22(5) 738-748.
3¡¢Peron A, et al. Am J Med Genet C Semin Med Genet.?2018?Sep;178(3):281-290.
4¡¢Ben-Menachem E.Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol ScandSuppl. 2011(192): 5¨C15, doi: 10.1111/j.1600-0404.2011.01596.x, indexed inPubmed: 22061176.
5¡¢°±¼ºÏ©Ëá˵Ã÷Êé
6¡¢Jackson MC,Jafarpour S, Klehm J, et al. Effect of vigabatrin on seizure control and safetyprofile in different subgroups of children with epilepsy. Epilepsia. 2017;58(9): 1575¨C1585.
7¡¢Ð¡¶ùÖØ¸´ÑÏÖØÑ¬È¾£ºÌá·À¡°ÂýÐÔÈâÑ¿Öײ¡£¬£¬£¬£¬£¬£¬£¬£¬¡¶¹«¹²Ò½Ñ§¡·? 2017ÄêµÚ5ÆÚ24-24
8¡¢çÑÒ«·¼.С¶ùÂýÐÔÈâÑ¿Öײ¡:£® ¡¶ ÍâÑóҽѧ.ÁÙ´²·ÅÉäѧ·Ö²á ¡· £¬£¬£¬£¬£¬£¬£¬£¬ 1990





